213 related articles for article (PubMed ID: 33732729)
1. Mesorectal Lymph Node Metastases as Index Lesion in
Leitsmann C; Schmid M; Sahlmann CO; Trojan L; Strauss A
Front Surg; 2021; 8():637134. PubMed ID: 33732729
[No Abstract] [Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. See the unseen: Mesorectal lymph node metastases in prostate cancer.
Hijazi S; Meller B; Leitsmann C; Strauss A; Ritter C; Lotz J; Meller J; Trojan L; Sahlmann CO
Prostate; 2016 Jun; 76(8):776-80. PubMed ID: 26880517
[TBL] [Abstract][Full Text] [Related]
4. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
5. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
6. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
7. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
Hijazi S; Meller B; Leitsmann C; Strauss A; Meller J; Ritter CO; Lotz J; Schildhaus HU; Trojan L; Sahlmann CO
Prostate; 2015 Dec; 75(16):1934-40. PubMed ID: 26356236
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
9. Randomized prospective phase III trial of
Calais J; Czernin J; Fendler WP; Elashoff D; Nickols NG
BMC Cancer; 2019 Jan; 19(1):18. PubMed ID: 30616601
[TBL] [Abstract][Full Text] [Related]
10.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
11. Recurrent prostate cancer: combined role for MRI and PSMA-PET in
Jannusch K; Bruckmann NM; Morawitz J; Boschheidgen M; Quick HH; Herrmann K; Fendler WP; Umutlu L; Stuschke M; Hadaschik B; Antoch G; Schimmöller L; Kirchner J
Eur Radiol; 2023 Dec; ():. PubMed ID: 38038758
[TBL] [Abstract][Full Text] [Related]
12. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
13. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
Natarajan A; Agrawal A; Murthy V; Bakshi G; Joshi A; Purandare N; Shah S; Puranik A; Rangarajan V
World J Nucl Med; 2019; 18(3):244-250. PubMed ID: 31516367
[TBL] [Abstract][Full Text] [Related]
14. Initial multicentre experience of
Siriwardana A; Thompson J; van Leeuwen PJ; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes AM; Coughlin G; Stricker P
BJU Int; 2017 Nov; 120(5):673-681. PubMed ID: 28548372
[TBL] [Abstract][Full Text] [Related]
15.
Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
[TBL] [Abstract][Full Text] [Related]
16. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
17. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
18. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
19.
Fassbind S; Ferraro DA; Stelmes JJ; Fankhauser CD; Guckenberger M; Kaufmann PA; Eberli D; Burger IA; Kranzbühler B
Ann Nucl Med; 2021 Oct; 35(10):1109-1116. PubMed ID: 34185262
[TBL] [Abstract][Full Text] [Related]
20. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
